Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]

Core Viewpoint - The collaboration between the company and Boji Pharmaceutical Technology Co., Ltd. marks a significant step in the company's strategic development in the innovative drug sector, focusing on the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - The company has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical, which will assist in completing the clinical research and registration of a Class 1 compound medicine [1] - This partnership is described as a strong alliance based on a shared development strategy, leveraging the strengths of both parties [1] Group 2: Advantages of Collaboration - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The collaboration is expected to create a synergistic effect, enhancing the research and development efficiency and success rate of the contracted product [1] - This partnership aims to lay a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - On September 25, Xiaofang Pharmaceutical experienced a decline of 5.1%, with a stock price of 33.68 CNY per share, a trading volume of 152 million CNY, a turnover rate of 8.09%, and a total market capitalization of 5.408 billion CNY [1]. Company Overview - Xiaofang Pharmaceutical Co., Ltd. is located at 777 Hongzhu Road, Fengxian District, Shanghai, and was established on August 12, 1993. The company went public on August 26, 2024. Its main business involves the research, production, and sales of external-use medications [1]. - The revenue composition of Xiaofang Pharmaceutical is as follows: digestive medications account for 51.05%, skin medications for 39.79%, ear, nose, and throat medications for 9.08%, and other supplementary products for 0.07% [1]. Shareholder Information - Among the top ten circulating shareholders of Xiaofang Pharmaceutical, one fund under Taixin Fund ranks as a significant shareholder. The Taixin Leading Strategy Mixed Fund (290002) held 256,800 shares in the second quarter, unchanged from the previous period, representing 0.64% of the circulating shares. The estimated floating loss today is approximately 464,800 CNY [2]. - The Taixin Leading Strategy Mixed Fund (290002) was established on June 28, 2004, with a current scale of 417 million CNY. Year-to-date returns are 21.85%, ranking 4285 out of 8173 in its category; the one-year return is 34.99%, ranking 4373 out of 8003; and since inception, the return is 172.88% [2]. - The fund manager of Taixin Leading Strategy Mixed Fund is Wang Boqiang, who has a cumulative tenure of 10 years and 196 days. The total asset scale under his management is 825 million CNY, with the best fund return during his tenure being 112.25% and the worst being -36.68% [2].

Core Insights - On September 10, Xiaofang Pharmaceutical experienced a decline of 2.44% with a trading volume of 124 million yuan [1] - The company reported a financing buy-in amount of 12.38 million yuan and a financing repayment of 14.91 million yuan, resulting in a net financing buy of -2.54 million yuan [1] - As of September 10, the total financing and securities lending balance for Xiaofang Pharmaceutical was 137 million yuan, which is 7.20% of its circulating market value, indicating a high level of financing [1] Financing Overview - On September 10, Xiaofang Pharmaceutical had a financing buy-in of 12.38 million yuan, with a current financing balance of 137 million yuan, exceeding the 90th percentile level over the past year [1] - In terms of securities lending, there were no shares repaid or sold on September 10, with a total securities lending balance of 0.00 yuan, also exceeding the 90th percentile level over the past year [1] Company Performance - As of June 30, the number of shareholders for Xiaofang Pharmaceutical was 14,800, a decrease of 22.41% from the previous period, while the average circulating shares per person increased by 28.88% to 2,703 shares [2] - For the first half of 2025, Xiaofang Pharmaceutical achieved a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit attributable to shareholders of 121 million yuan, with a year-on-year increase of 1.69% [2] Dividend and Shareholding Structure - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 241 million yuan in dividends [3] - As of June 30, 2025, among the top ten circulating shareholders, CITIC Jiantou Rotation Mixed A (003822) ranked as the third-largest shareholder with 439,400 shares, while CITIC Jiantou Selected Mixed A (008347) was the fourth-largest with 298,100 shares, both being new shareholders [3]

Core Viewpoint - The company Xiaofang Pharmaceutical has shown stable financial performance with a slight increase in revenue and net profit, while also experiencing significant activity in its financing and stockholder structure [1][2][3]. Financing and Stock Performance - On September 8, Xiaofang Pharmaceutical's stock rose by 0.37% with a trading volume of 85.47 million yuan, and the net financing purchase amounted to 3.43 million yuan [1]. - The total financing and securities balance reached 127 million yuan, accounting for 6.73% of the circulating market value, indicating a high level of financing activity [1]. - The company had no short-selling activity on September 8, with a short-selling balance of 0, reflecting a lack of bearish sentiment [1]. Financial Performance - For the first half of 2025, Xiaofang Pharmaceutical reported a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit attributable to shareholders of 121 million yuan, up by 1.69% [2]. - Cumulative cash dividends since the company's A-share listing have reached 241 million yuan [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 22.41% to 14,800, while the average circulating shares per person increased by 28.88% to 2,703 shares [2]. - Notable institutional investors include CITIC Jiantou Rotation Mixed A and CITIC Jiantou Selection Mixed A, both of which are new major shareholders [3].

Core Viewpoint - The company, Shanghai Xiaofang Pharmaceutical Co., Ltd., is set to hold an investor briefing on September 12, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [2][3][4]. Group 1: Meeting Details - The investor briefing will take place on September 12, 2025, from 11:00 AM to 12:00 PM [5][6]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [2][4]. - Investors can submit questions from September 5 to September 11, 2025, through the Roadshow Center website or via the company's email [4][6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [5][6]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with the investor community [3][4].

Group 1 - The company, Xiaofang Pharmaceutical (603207), announced that it will hold a half-year performance briefing on September 12, 2025 [1]

Core Points - The company will hold a half-year performance briefing on September 12, 2025, from 11:00 to 12:00 [1] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1] - Investors can submit questions from September 5 to September 11, 2025, via the company's email or the Roadshow Center's website [1] Meeting Details - The meeting is scheduled for September 12, 2025, from 11:00 to 12:00 [1] - Location: Shanghai Stock Exchange Roadshow Center [1] - Format: Online interactive session [1] Participants - Key attendees include the Chairman and General Manager Fang Zhiguang, Secretary of the Board and Financial Officer Luo Xiaoxu, and Independent Director Yu Wei [1] Investor Participation - Investors can join the meeting online on September 12, 2025, and will have the opportunity to ask questions [1] - Questions can be submitted in advance through the Roadshow Center's website or via the company's email [1] Contact Information - Contact person: Jiang Lili, Phone: 021-50818259, Email: info@xf-pharma.com [1] Additional Information - After the briefing, investors can access the meeting details and main content through the Shanghai Stock Exchange Roadshow Center [1]

关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 证券代码：603207 证券简称：小方制药 公告编号:2025-033 上海小方制药股份有限公司 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 09 月 12 日（星期五）11:00-12:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 09 月 05 日（星期五）至 09 月 11 日（星期四） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 info@xf-pharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 上海小方制药股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入 地了解公司 2025 年半年度经营成 ...

Core Viewpoint - On September 2, Xiaofang Pharmaceutical experienced a decline of 1.26% in stock price, with a trading volume of 93.99 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On the same day, Xiaofang Pharmaceutical had a financing buy-in amount of 17.32 million yuan, with a financing repayment of 9.77 million yuan, resulting in a net financing buy-in of 7.55 million yuan [1]. - As of September 2, the total financing and securities lending balance for Xiaofang Pharmaceutical reached 126 million yuan, with the current financing balance accounting for 6.73% of the circulating market value [1]. Company Overview - Xiaofang Pharmaceutical, established on August 12, 1993, is located in Shanghai and specializes in the research, production, and sales of external-use medications [1]. - The company's revenue composition is as follows: digestive medications 51.05%, skin medications 39.79%, otorhinolaryngology medications 9.08%, and others 0.07% [1]. Financial Performance - For the first half of 2025, Xiaofang Pharmaceutical reported a revenue of 270 million yuan, reflecting a year-on-year growth of 3.06%, while the net profit attributable to shareholders was 121 million yuan, showing a growth of 1.69% [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xiaofang Pharmaceutical was 14,800, a decrease of 22.41% from the previous period, while the average circulating shares per person increased by 28.88% to 2,703 shares [1]. - The company has distributed a total of 241 million yuan in dividends since its A-share listing [2]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, CITIC Jiantou Rotation Mixed A (003822) ranked as the third-largest shareholder with 439,400 shares, being a new shareholder [2]. - CITIC Jiantou Selection Mixed A (008347) was the fourth-largest shareholder with 298,100 shares, also a new addition, while Taixin First Strategy Mixed (290002) remained the fifth-largest shareholder with 256,800 shares, unchanged from the previous period [2].